The state of the psychoemotional sphere in patients with inflammatory bowel diseases


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Inflammatory bowel diseases are chronic diseases of unknown etiology that occur with periods of exacerbations and remissions, leading to negative consequences in the social, physical and emotional spheres, reducing the quality of life and thereby exacerbating the course of the disease, increasing the risk of exacerbations and relapses. An obvious fact is that a significant number of factors influence the state of psychological status and the level of quality of life, including the nosology itself (most often Crohn's disease is more severe, especially with the debut in young patients), the severity of the course of the disease, the extent of the lesion of the digestive tube, extraintestinal manifestations, complications, surgical interventions, as well as the effectiveness of the selected therapy. In this article, we analyzed the available domestic and foreign literature, tried to identify risk factors that contribute to a negative impact on the quality of life, and described possible methods for alleviating psychopathological symptoms. Currently, there is no available and effective drug therapy that directly affects the quality of life of patients. Most likely, a positive impact on the quality of life will be largely associated with the activity and severity of the underlying disease.

Full Text

Restricted Access

About the authors

Yu. P Uspensky

St. Petersburg State Pediatric Medical University; Pavlov University

Yu. A Fominykh

St. Petersburg State Pediatric Medical University; Pavlov University

Olga A. Kizimova

St. Petersburg State Pediatric Medical University

Email: olya.kizimova.95@mail.ru
Teaching Assistant at the Department of Faculty Therapy n.a. V.A. Valdman

N. Yu Kolgina

Tver State Medical University

References

  1. Yin S., Njai R., Barker L., et al. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. Popul Health Metr. 2016;14:22. doi: 10.1186/s12963-016-0091-3.
  2. Успенский Ю.П., Древаль Р.О., Иванов С.В. Болезнь Крона: фармакоэкономические аспекты ведения пациентов. University Therapeutic Journal. 2020;2(1):98-9.
  3. Larsson K., L.F.L., Ronnblom A., et al. Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J. Psychosomat Res. 2008;64(2):139-48. doi: 10.1016/j.jpsychores.2007.10.007.
  4. Min Ho P.Y., Hu W.ю, Lee Y.Y., et al. Health-related quality of life of patients with inflammatory bowel disease in Singapore. Intest Res. 2019;17(1):107- 18. doi: 10.5217/ir.2018.00099.
  5. Van Assche G., Peyrin-Biroulet L., Sturm A., et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. Dig Liver Dis. 2016;48(6):592-600. doi: 10.1016/j.dld.2016.01.011.
  6. Van de star T., Banan A. Role of Psychosocial Factors on the Course of Inflammatory Bowel Disease and Associated Psychotherapeutic Approaches. A Fresh Perspective and Review. Gastroenterol Hepatol Open Access. 2015;2(2):00038. doi: 10.15406/ghoa.2015.02.00038.
  7. Graff L.A., Walker J.R., Clara I., et al. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J. Gastroenterol. 2009;104(12):2959-69. doi: 10.1038/ajg.2009.529.
  8. Успенский Ю.П., Фоминых Ю.А., Гнутов А.А. Поражения полости рта при воспалительных заболеваниях кишечника. Врач. 2021;32(10):25-8. doi: 10.29296/25877305-2021-10-04.
  9. Князев О.В., Болдырева О.Н., Парфенов А.И. и др. Качество жизни больных воспалительными заболеваниями кишечника. Экспериментальная и клиническая гастроэнтерология. 2021;9.
  10. Qin Cao, Yu-Hong H., Jiang M., et al. The prevalence and risk factors of psychological disorders, malnutrition and quality of life in IBD patients. Scand J. Gastroenterol. 2019;54(12):1458-66. doi: 10.1080/00365521.2019.1697897.
  11. Pulley J., Todd A., Flatley C., et al. Malnutrition and quality of life among adult inflammatory bowel disease patients. J. Gastroenterol Hepatol. 2019;4(3):454-60. doi: 10.1002/jgh3.12278.
  12. Parra R. S., Chebli J. M.F., Amarante M.B.S., et al. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J. Gastroenterol. 2019;25(38):5862-82. doi: 10.3748/wjg.v25. i38.5862.
  13. Hughes L. D., King L., Morgan M., et al. Food-related Quality of Life in Inflammatory Bowel Disease: Development and Validation of a Questionnaire. J. Crohns Colitis. 2016;10(2):194-201. doi: 10.1093/ecco-jcc/jjv192.
  14. Whelan K., Murrells T., Morgan M.et al. Food-related quality of life is impaired in inflammatory bowel disease and associated with reduced intake of key nutrients. Am J. Clin Nutr. 2021;113(4):832-44. doi: 10.1093/ajcn/ nqaa395.
  15. Greuter T., Manser C., Pittet V. et al. Gender Differences in Inflammatory Bowel Disease. Digestion. 2020;101:98-104. doi: 10.1159/000504701.
  16. Hauser G., Tkalcic M., Stimacetal D. Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. CollAntropol. 2011;35:203-7.
  17. Shah S. C., Khalili H., Gower-Rousseau C., et al. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology. 2018;155(4):1079-89. doi: 10.1053/j.gastro.2018.06.043.
  18. Vi god S. N., Kurdyak P., Brown H. K. et al. Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut. 2019;68(9):1597-605. Doi: 10.1136/ gutjnl-2018-317610.
  19. Fousekisa FS., Katsanosb A. H., Kourtis G., et al. Inflammatory Bowel Disease and Patients With Mental Disorders: What Do We Know? J. Clin Med Res. 2021;13(9):466-73. Doi: 10.14740/ jocmr4593.
  20. Nurmi E., Haapamaki J., Paavilainen E., et al. The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J. Gastroenterol. 2013;48(1):51-7. doi: 10.3109/00365521.2012.685750.
  21. Fagan G., Osborne H., Schultz M. Physical Activity in Patients with Inflammatory Bowel Disease: A Cross-Sectional Study. Inflamm Intest Dis. 2021;6(2):61-69. doi: 10.1159/000511212.
  22. DeFilippis E.M., Tabani S., Warren R.U., et al. Exercise and Self-Reported Limitations in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2016;61(1):215-20. doi: 10.1007/s10620- 015-3832-4.
  23. Vogelaar L., van den Berg-Emons R., Bussmann H., et al. Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients. Scand J. Gastroenterol. 2015;50(11):1357-67. doi: 10.3109/00365521.2015.1046135.
  24. Sobolewska-Wlodarczyk A., Wlodarczyk M., Banasik J., et al. Sleep disturbance and disease activity in adult patients with inflammatory bowel diseases. J. Physiol Pharmacol. 2018;69(3). doi: 10.26402/jpp.2018.3.09.
  25. Marinelli C., Savarino E.V., Marsilio I., et al. Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors - A cross-sectional study Sci Rep. 2020;10(1):507. Doi: 10.1038/ s41598-020-57460-6.
  26. Zhang Y., Pi B., Xu X., et al. Sleep Characteristics and Influencing Factors of Sleep Quality in Patients With Inflammatory Bowel Disease-Peripheral Arthritis. Front Med (Lausanne). 2020;6:190. doi: 10.3389/fmed.2019.00190.
  27. Sochal M., Matecka-Panas E., Gabryelska A., et al. Determinants of Sleep Quality in Inflammatory Bowel Diseases. J. Clin Med. 2020;9(9):2921. doi: 10.3390/jcm9092921.
  28. Riviere P., Zallot C., Desobry P., et al. Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease. J. Crohns Colitis. 2017;11(11):1347-52. Doi: 10.10Q3/ecco-jcc/jjxl00.
  29. Friedman S., Magnussen B., O. Toole A., et al. Increased Use of Medications for Erectile Dysfunction in Men With Ulcerative Colitis and Crohn's Disease Compared to Men Without Inflammatory Bowel Disease: A Nationwide Cohort Study. Am J. Gastroenterol. 2018;113(9):1355. doi: 10.1038/s41395-018-0177-6.
  30. Perez de Arce E., Quera R., Ribeiro Barros J., Yukie Sassaki L. Sexual Dysfunction in Inflammatory Bowel Disease: What the Specialist Should Know and Ask. Int J. Gen Med. 2021;14:2003-2015. doi: 10.2147/IJGM.S308214.
  31. Shmidt E., Su rez-Fari as M., Mallette M., et al. Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(8):1408-1416. doi: 10.1093/ibd/izy401.
  32. Shmidt E., Suarez-Farinas M., Mallette M., et al. A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(7):1262-1270. doi: 10.1093/ibd/izy397.
  33. Muller K.R., Prosser R., Bampton P., et al. Female gender and surgery impair relationships, body image, and sexuality in inflammatory bowel disease: patient perceptions. Inflamm Bowel Dis. 2010;16(4):657-63. doi: 10.1002/ibd.21090.
  34. N0hr E.A., Nielsen J., Nergard B.M., Friedman S. Sexual Health in Women with Inflammatory Bowel Disease in the Danish National Birth Cohort. J. Crohns Colitis. 2020;14(8):1082-89. Doi: 10.10QЗ/'occo-jcc/jjac038.
  35. Beese S.E., Harris I.M., Moore D., Dretzke J. Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review protocol. Syst Rev. 2018;7(1):184. doi: 10.1186/s13643-018-0844-0.
  36. McDermott E., Mullen G., Moloney J., et al. Body image dissatisfaction: clinical features, and psychosocial disability in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(2):353-60. doi: 10.1097/MIB.0000000000000287.
  37. PinetondeChambrun G., Liberatore M., Buisson A., et al. P701 Quality of life of patients with inflammatory bowel diseases who live with an ostomy: Results of a French national survey. J. Crohn’s Colitis. 2018;12(suppl 1):S466. doi: 10.1093/ecco-jcc/jjx180.828.
  38. Abdalla M.I., Sandler R.S., Kappelman M.D., et al. The Impact of Ostomy on Quality of Life and Functional Status of Crohn’s Disease Patients. Inflamm Bowel Dis. 2016;22(ll):2658-64. doi: 10.1097/MIB.0000000000000930.
  39. Sceats L.A., Dehghan M.S., Rumer K.K., et al. Surgery, stomas, and anxiety and depression in inflammatory bowel disease: a retrospective cohort analysis of privately insured patients. Colorectal Dis. 2020;22(5):544-53. doi: 10.1111/codi.14905.
  40. Seminerio J., Binion D. P-070 Impact of Obesity on Inflammatory Bowel Disease: Metabolic, Clinical and Therapeutic Implications. Inflamm Bowel Dis. 2013;19:S54. doi: 10.1097/01. MIB.0000438749.89898.31.
  41. Успенский Ю.П., Иванов С.В., Майорова О.В. и др. Воспалительные заболевания кишечника и ожирение. University Therapeutic Journal. 2020;2(1):71-2.
  42. Rozich J.J., Holmer A., Singh S. Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases. Am J. Gastroenterol. 2020; 115(6):832-40. Doi: 10.14309/ ajg.0000000000000608.
  43. Grimstad T., Norheim K.B., Isaksen K., et al. Fatigue in Newly Diagnosed Inflammatory Bowel Disease. J. Crohns Colitis. 2015;9(9):725-30. doi: 10.1093/ecco-jcc/jjv091.
  44. Huppertz-Hauss G., Heivik M.L., Jelsness-Jergensen L.P., et al. Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study Scand J. Gastroenterol. 2017;52(3):351-58. doi: 10.1080/00365521.2016.1256425. Epub 2016 Nov 17. Erratum in: Scand J. Gastroenterol. 2017;52(5):i.
  45. Pellino G., Sciaudone G., Caserta V., et al. Fatigue in inflammatory bowel diseases: relationship with age and disease activity. Int J. Surg. 2014;12(Suppl 2):S60-S63. doi: 10.1016/j.ijsu.2014.08.379.
  46. Jelsness-J0rgensen L.P., Bernklev T., Henriksen M., et al. Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls. Inflamm Bowel Dis. 2011;17(7):1564-72. doi: 10.1002/ibd.21530.
  47. Grimstad T., Norheim K.B. Fatigue in inflammatory bowel disease. Tidsskr Nor Laegeforen. 2016;136(20):1721-24. English, Norwegian. doi: 10.4045/tidsskr.16.0134.
  48. Saraiva S., Cortez-Pinto J., Barosa R., et al. Evaluation of fatigue in inflammatory bowel disease - a useful tool in daily practice. Scand J. Gastroenterol. 2019;54(4):465-70. doi: 10.1080/00365521.2019.1602669.
  49. Tasson L., Zingone F., Barberio B., et al. Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. Sci Rep. 2021;11(1):15251. doi: 10.1038/s41598-021-94685-5.
  50. Nurmi E., Haapamaki J., Paavilainen E., et al. The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J. Gastroenterol. 2013;48(1):51-7. doi: 10.3109/00365521.2012.685750.
  51. Nocerino A., Nguyen A., Agrawal M., et al. Fatigue in Inflammatory Bowel Diseases: Etiologies and Management. Adv Ther. 2020;37(1):97-112. doi: 10.1007/s12325-019-01151-w.
  52. Lakhan S.E., Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond). 2010;7:79. doi: 10.1186/1743-7075-7-79.
  53. Sun Y., Li L., Xie R., et al. Stress Triggers Flare of Inflammatory Bowel Disease in Children and Adults. Front Pediatr. 2019;7:432. doi: 10.3389/ fped.2019.00432.
  54. Navabi S., Gorrepati VS., Yadav S., et al. Influences and Impact of Anxiety and Depression in the Setting of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(11):2303-2308. doi: 10.1093/ibd/izy143.
  55. Kozka M., Skowron W., Bodys-Cupak I. Determinants of the level of anxiety and fears in a group of patients with ulcerative colitis. Ann Agric Environ Med. 2019;26(2):337-340. doi: 10.26444/aaem/94651.
  56. Hauser W., Janke K.H., Klump B., Hinz A. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis. 2011;17(2):621-32. doi: 10.1002/ibd.21346.
  57. Greuter T., Manser C., Pittet V., et al.; on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Gender Differences in Inflammatory Bowel Disease. Digestion. 2020;101(Suppl 1):98-104. doi: 10.1159/000504701.
  58. Mittermaier C., Dejaco C., Waldhoer T., et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004;66(1):79-84. doi: 10.1097/01. psy.0000106907.24881.f2.
  59. Lee J.W. Anxiety and Depression in Patients with Inflammatory Bowel Diseases: The First Step toward Proper Management. Gut Liver. 2020;14(4):395-96. doi: 10.5009/gnl20187.
  60. Byrne G., Rosenfeld G., Leung Y., et al. Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease. Can J. Gastroenterol Hepatol. 2017;2017:6496727. doi: 10.1155/20 1 7/649 6727.
  61. Neuendorf R., Harding A., Stello N., et al. Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review. J. Psychosom Res. 2016;87:70-80. doi: 10.1016/j.jpsychores.2016.06.001.
  62. Enns M.W., Bernstein C.N., Kroeker K., et al.; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. PLoS One. 2018;13(6):e0198975. doi: 10.1371/journal. pone.Qie.8995.
  63. Taylor K., Scruggs P.W., Balemba O.B., et al. Associations between physical activity, resilience, and quality of life in people with inflammatory bowel disease. Eur J. Appl Physiol. 2018;118(4):829-36. doi: 10.1007/s00421-018-3817-z.
  64. Kim B., Chae J., Kim E.H., et al. Physical activity and quality of life of patients with inflammatory bowel disease. Medicine (Baltimore). 2021;100(27):e26290. Doi: 10.1097/ MD.0000000000026290.
  65. Paulides E., Boukema I., van der Woude C.J., de Boer N.K.H. The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review. Inflamm Bowel Dis. 2021;27(5):711-24. doi: 10.1093/ibd/izaa144.
  66. Wynne B., McHugh L., Gao W., et al. Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2019;156(4):935-45.e1. doi: 10.1053/j.gastro.2018.11.030.
  67. Kafil T.S., Nguyen T.M., MacDonald J.K., Chande N. Cannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews. Inflamm Bowel Dis. 2020;26(4):502-9. doi: 10.1093/ibd/izz233.
  68. Macer B.J., Prady S.L., Mikocka-Walus A. Antidepressants in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2017;23(4):534-50. Doi: 10.1097/ MIB.0000000000001059.
  69. Mikocka-Walus A.A., Turnbull D.A., Moulding N.T., et al. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health. 2006;2:24. doi: 10.1186/17450179-2-24.
  70. Docherty M.J., Jones R.C. 3rd, Wallace M.S. Managing pain in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011; 7(9):592-601.
  71. Mikocka-Walus A., Ford A.C., Drossman D.A. Antidepressants in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(3):184-92. doi: 10.1038/s41575-019-0259-y.
  72. Mikocka-Walus A.,Prady S.L., Pollok J.,etalAdjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev. 2019;4(4):CD012680. doi: 10.1002/14651858.CD012680.pub2.
  73. Mikocka-Walus A., Hughes PA., Bampton P., et al. Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial. J. Crohns Colitis. 2017;11(4):509-14. doi: 10.1093/eccQ-jcc/jjw165.
  74. Dejban P., Sahraei M., Chamanara M., et al. Antiinflammatory effect of amitriptyline in a rat model of acetic acid-induced colitis: the involvement of the TLR4/NF-kB signaling pathway. Fundam Clin Pharmacol. 2021;35(5):843-51. Doi: 10.1111/ fcp.12642.
  75. Fattahian E., Hajhashemi V., Rabbani M., et al. Anti-inflammatory Effect of Amitriptyline on Ulcerative Colitis in Normal and Reserpine-Induced Depressed Rats. Iran J. Pharm Res. 2016;15(Suppl):125-37.
  76. Kast R.E. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry. 2003;25(6):495-96. doi: 10.1016/s0163-8343(03)00093-8.
  77. Kast R.E., Altschuler E.L. Remission of Crohn’s disease on bupropion. Gastroenterology. 2001;121 (5):1260-61. Doi: 10.1053/ gast.2001.29467.
  78. Hashash J.G., Knisely M.R., Germain A., et al. Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study. Clin Gastroenterol Hepatol. 2022;20(1):96-104. Doi: 10.1016/j. cgh.2020.09.047.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies